News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Miraculins Inc. (MOM) and Cachet Sign LOI for China Rights to Diabetes Test



10/16/2013 8:18:24 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

by Richard Daverman, PhD

October 15, 2013 -- Miraculins, a Canadian maker of non-invasive diagnostic tests, has signed a Letter of Intent to sell China rights for a diabetes test to Cachet Pharma, a China drug distributor. Miraculins acquired rights to the SCOUT DS® technology less than two months ago. SCOUT is a non-invasive test that measures changes in a person’s skin to indicate prediabetes and diabetes type 2. More details....

Stock Symbols: (TSX-V: MOM) (SHE: 002462)

Help employers find you! Check out all the jobs and post your resume.

Read at ChinaBio Today


comments powered by Disqus
   
Diabetes

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES